Original Articles
26 June 2025
Vol. 57 No. s4 (2005)
https://doi.org/10.4081/reumatismo.2005.4s.30

Approved indications and other possible utilizations of anti-TNFa biologic drugs

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1131
Views
872
Downloads

Authors

W. Grassi
office@pagepress.org
C. Montecucco
The article describes the EMEA approved indications of TNFa antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFa antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



Approved indications and other possible utilizations of anti-TNFa biologic drugs. (2005). Reumatismo, 57(s4), 30-33. https://doi.org/10.4081/reumatismo.2005.4s.30

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.